{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:19:09Z","timestamp":1793254749237,"version":"4.5.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.det.2022.07.017","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T07:02:27Z","timestamp":1666940547000},"page":"49-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Melanoma classification and management in the era of molecular medicine"],"prefix":"10.1016","volume":"41","author":[{"given":"Sarem","family":"Rashid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hensin","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1242\/dev.106567","article-title":"The melanocyte lineage in development and disease","volume":"142","author":"Mort","year":"2015","journal-title":"Development"},{"issue":"7130","key":"10.1016\/j.det.2022.07.017_bib2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nature05660","article-title":"Melanocyte biology and skin pigmentation","volume":"445","author":"Lin","year":"2007","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib3","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41467-021-21576-8","article-title":"Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling","volume":"12","author":"Vergara","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib5","first-page":"572","article-title":"Survival rates of patients with metastatic malignant melanoma","volume":"7","author":"Sandru","year":"2014","journal-title":"J\u00a0Med Life"},{"key":"10.1016\/j.det.2022.07.017_bib6","series-title":"Cutaneous melanoma: etiology and therapy","article-title":"Surgical Management of Melanoma","author":"Joyce","year":"2017"},{"issue":"9","key":"10.1016\/j.det.2022.07.017_bib7","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/archsurg.139.9.961","article-title":"Contemporary surgical treatment of advanced-stage melanoma","volume":"139","author":"Essner","year":"2004","journal-title":"Arch Surg"},{"issue":"11","key":"10.1016\/j.det.2022.07.017_bib8","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1586\/era.10.170","article-title":"A\u00a0new understanding in the epidemiology of melanoma","volume":"10","author":"Erdei","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/archderm.1996.03890280098014","article-title":"Prevention and early detection strategies for melanoma and skin cancer. Current status","volume":"132","author":"Koh","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2022.07.017_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.freeradbiomed.2016.10.488","article-title":"Oxidatively-generated damage to DNA and proteins mediated by photosensitized UVA","volume":"107","author":"Brem","year":"2017","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1751-1097.1984.tb04622.x","article-title":"Transmission of human epidermis and stratum corneum as a function of thickness in the ultraviolet and visible wavelengths","volume":"40","author":"Bruls","year":"1984","journal-title":"Photochem Photobiol"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib12","first-page":"1071","article-title":"Cutaneous melanoma: From pathogenesis to therapy (Review)","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int J Oncol"},{"issue":"5","key":"10.1016\/j.det.2022.07.017_bib13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaad.2016.06.006","article-title":"Racial disparities in melanoma survival","volume":"75","author":"Dawes","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2022.07.017_bib14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2147\/CCID.S311694","article-title":"Racial Disparities in Patients with Melanoma: A Multivariate Survival Analysis","volume":"14","author":"Brady","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1200\/JCO.2007.12.3604","article-title":"Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment","volume":"26","author":"Zell","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2022.07.017_bib16","series-title":"StatPearls","article-title":"Acral Lentiginous Melanoma","author":"Hall","year":"2022"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib17","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/s12885-016-2747-6","article-title":"Racial differences in six major subtypes of melanoma: descriptive epidemiology","volume":"16","author":"Wang","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/pcmr.12885","article-title":"Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease","volume":"34","author":"Basurto-Lozada","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/archdermatol.2008.609","article-title":"Acral Lentiginous Melanoma: Incidence and Survival Patterns in the United States, 1986-2005","volume":"145","author":"Bradford","year":"2009","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.det.2022.07.017_bib20","first-page":"375","article-title":"Doses of solar ultraviolet radiation correlate with skin cancer rates in Japan","volume":"42","author":"Suzuki","year":"1996","journal-title":"Kobe J Med Sci"},{"issue":"3","key":"10.1016\/j.det.2022.07.017_bib21","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clinicians"},{"issue":"3","key":"10.1016\/j.det.2022.07.017_bib22","first-page":"234","article-title":"Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand","volume":"5","author":"Bulliard","year":"1994","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12942-019-0185-9","article-title":"Development of the Australian Cancer Atlas: spatial modelling, visualisation, and reporting of estimates","volume":"18","author":"Duncan","year":"2019","journal-title":"Int J Health Geogr"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjd.12492","article-title":"Emerging trends in the epidemiology of melanoma","volume":"170","author":"Nikolaou","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2022.07.017_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jdin.2020.10.013","article-title":"The global burden of skin cancer: A longitudinal analysis from the Global Burden of Disease Study, 1990-2017","volume":"2","author":"Urban","year":"2021","journal-title":"JAAD Int"},{"issue":"12","key":"10.1016\/j.det.2022.07.017_bib27","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1038\/jid.2008.159","article-title":"Recent trends in incidence of cutaneous melanoma among U.S. Caucasian young adults","volume":"128","author":"Purdue","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"issue":"14","key":"10.1016\/j.det.2022.07.017_bib28","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2011.39.3652","article-title":"Use of Tanning Beds and Incidence of Skin Cancer","volume":"30","author":"Zhang","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.det.2022.07.017_bib29","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/jamadermatol.2013.4408","article-title":"Melanoma Survival Disadvantage in Young, Non-Hispanic White Males Compared With Females","volume":"149","author":"Gamba","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2022.07.017_bib30","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1158\/1055-9965.EPI-04-0632","article-title":"Risk factors for melanoma by body site","volume":"14","author":"Cho","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"10.1016\/j.det.2022.07.017_bib31","first-page":"3081","article-title":"Primary Locations of Malignant Melanoma Lesions Depending on Patients\u2019 Gender and Age","volume":"18","author":"Stanienda-Sok\u00f3\u0142","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/CMR.0b013e32832e0b81","article-title":"The anatomic distribution of melanoma and relationships with childhood nevus distribution in Colorado","volume":"19","author":"Juhl","year":"2009","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.det.2022.07.017_bib33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/120347540000400202","article-title":"Sex differences in the anatomical distribution of melanocytic nevi in Canadian Hutterite children","volume":"4","author":"Kwan","year":"2000","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.det.2022.07.017_bib34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/pcmr.12820","article-title":"Body site-specific genetic effects influence naevus count distribution in women","volume":"33","author":"Visconti","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CMR.0b013e32834e6aa0","article-title":"Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model","volume":"22","author":"Greenwald","year":"2012","journal-title":"Melanoma Res"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib36","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg"},{"issue":"9","key":"10.1016\/j.det.2022.07.017_bib37","first-page":"706","article-title":"Nodular melanoma. No longer as simple as ABC","volume":"32","author":"Kelly","year":"2003","journal-title":"Aust Fam Physician"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/archdermatol.2011.264","article-title":"The contribution of nodular subtype to melanoma mortality in the United States, 1978 to 2007","volume":"148","author":"Shaikh","year":"2012","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.det.2022.07.017_bib39","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/jdv.17135","article-title":"Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10-year follow-up at a tertiary centre","volume":"35","author":"Collgros","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2022.07.017_bib40","series-title":"Clinical characteristics","author":"Morton","year":"2003"},{"issue":"5","key":"10.1016\/j.det.2022.07.017_bib41","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1097-0142(196805)21:5<893::AID-CNCR2820210513>3.0.CO;2-8","article-title":"Melanotic freckle of Hutchinson","volume":"21","author":"Wayte","year":"1968","journal-title":"Cancer"},{"key":"10.1016\/j.det.2022.07.017_bib42","series-title":"Cutaneous melanoma: etiology and therapy","article-title":"Clinical Presentation and Staging of Melanoma","author":"Ward","year":"2017"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib43","first-page":"65","article-title":"Nevus-associated melanoma: facts and controversies","volume":"155","author":"Pampena","year":"2020","journal-title":"G\u00a0Ital Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaad.2014.09.028","article-title":"Outcome of patients with de novo versus nevus-associated melanoma","volume":"72","author":"Lin","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2022.07.017_bib45","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/archderm.139.3.282","article-title":"The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate","volume":"139","author":"Tsao","year":"2003","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1016\/j.det.2022.07.017_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw121","article-title":"De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival","volume":"108","author":"Cymerman","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.det.2022.07.017_bib47","series-title":"AJCC cancer staging manual","year":"2017"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41379-019-0402-x","article-title":"Melanoma pathology reporting and staging","volume":"33","author":"Scolyer","year":"2020","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.det.2022.07.017_bib49","first-page":"472","article-title":"Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/jclinpath-2018-205417","article-title":"Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters","volume":"72","author":"Trinidad","year":"2019","journal-title":"J\u00a0Clin Pathol"},{"issue":"12","key":"10.1016\/j.det.2022.07.017_bib51","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1002\/1097-0142(19800615)45:12<3012::AID-CNCR2820451223>3.0.CO;2-O","article-title":"The prognostic significance of ulceration of cutaneous melanoma","volume":"45","author":"Balch","year":"1980","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.det.2022.07.017_bib52","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1200\/JCO.2004.03.075","article-title":"Impact of Ulceration in Stages I to III Cutaneous Melanoma As Staged by the American Joint Committee on Cancer Staging System: An Analysis of the German Central Malignant Melanoma Registry","volume":"22","author":"Eigentler","year":"2004","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.det.2022.07.017_bib53","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3892\/or.2014.3531","article-title":"Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: A 5-year survival analysis","volume":"32","author":"Donizy","year":"2014","journal-title":"Oncol Rep"},{"issue":"16","key":"10.1016\/j.det.2022.07.017_bib54","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1200\/JCO.2010.31.5812","article-title":"Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database","volume":"29","author":"Thompson","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib55","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0753-3322(01)00052-X","article-title":"Occult metastasis","volume":"55","author":"Hawes","year":"2001","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.det.2022.07.017_bib56","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/s41379-020-0500-9","article-title":"The prognostic significance of microsatellites in cutaneous melanoma","volume":"33","author":"Niebling","year":"2020","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.det.2022.07.017_bib57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","article-title":"In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy","volume":"22","author":"Read","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.det.2022.07.017_bib58","doi-asserted-by":"crossref","first-page":"981","DOI":"10.4065\/mcp.2011.0287","article-title":"Circulating Serologic and Molecular Biomarkers in Malignant Melanoma","volume":"86","author":"Palmer","year":"2011","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.det.2022.07.017_bib59","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2345::AID-CNCR8>3.0.CO;2-K","article-title":"Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors","volume":"79","author":"Brand","year":"1997","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.det.2022.07.017_bib60","first-page":"193","article-title":"Prognostic factors in 1,521 melanoma patients with distant metastases","volume":"181","author":"Barth","year":"1995","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.det.2022.07.017_bib61","doi-asserted-by":"crossref","unstructured":"Gupta S, Tsao H. Epidemiology of Melanoma. In: ; 2017. doi:10.1007\/978-3-319-35153-7_31.","DOI":"10.1007\/978-3-319-35153-7_31"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib62","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2022.07.017_bib63","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/healthcare2020234","article-title":"Update and Review on the Surgical Management of Primary Cutaneous Melanoma","volume":"2","author":"Niknam Leilabadi","year":"2014","journal-title":"Healthcare (Basel)"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib64","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","article-title":"Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Coit","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.det.2022.07.017_bib65","series-title":"StatPearls","article-title":"Clinical Guidelines For The Staging, Diagnosis, and Management Of Cutaneous Malignant Melanoma","author":"Pathak","year":"2022"},{"issue":"11","key":"10.1016\/j.det.2022.07.017_bib66","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/cncr.22320","article-title":"Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma","volume":"107","author":"Gannon","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cps.2009.07.002","article-title":"Complete lymph node dissection for regional nodal metastasis","volume":"37","author":"Dzwierzynski","year":"2010","journal-title":"Clin Plast Surg"},{"issue":"6","key":"10.1016\/j.det.2022.07.017_bib68","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6892","key":"10.1016\/j.det.2022.07.017_bib69","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"15_suppl","key":"10.1016\/j.det.2022.07.017_bib70","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1200\/jco.2011.29.15_suppl.8597","article-title":"Frequency of mutations associated with targeted therapy in malignant melanoma patients","volume":"29","author":"Cheng","year":"2011","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib71","first-page":"1103","article-title":"BRAF in malignant melanoma progression and metastasis: potentials and challenges","volume":"10","author":"Alqathama","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"7","key":"10.1016\/j.det.2022.07.017_bib72","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/bjc.2016.44","article-title":"BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival","volume":"114","author":"Hugdahl","year":"2016","journal-title":"Br J Cancer"},{"issue":"24","key":"10.1016\/j.det.2022.07.017_bib73","doi-asserted-by":"crossref","first-page":"36130","DOI":"10.18632\/oncotarget.9143","article-title":"Which melanoma patient carries a BRAF-mutation? A comparison of predictive models","volume":"7","author":"Eigentler","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.det.2022.07.017_bib74","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib75","first-page":"21","article-title":"Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview","volume":"19","author":"Serrone","year":"2000","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.det.2022.07.017_bib76","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"New Engl J Med"},{"issue":"7377","key":"10.1016\/j.det.2022.07.017_bib77","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.det.2022.07.017_bib78","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.2147\/OTT.S182721","article-title":"Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma","volume":"11","author":"Kakadia","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"7326","key":"10.1016\/j.det.2022.07.017_bib79","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"issue":"10240","key":"10.1016\/j.det.2022.07.017_bib80","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.det.2022.07.017_bib81","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib82","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.det.2022.07.017_bib83","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.det.2022.07.017_bib84","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib85","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/exd.12054","article-title":"High-throughput sequencing of the melanoma genome","volume":"22","author":"Kunz","year":"2013","journal-title":"Exp Dermatol"},{"issue":"7","key":"10.1016\/j.det.2022.07.017_bib86","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1517\/14656566.2016.1168805","article-title":"Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations","volume":"17","author":"Spain","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"10.1016\/j.det.2022.07.017_bib87","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrclinonc.2011.69","article-title":"BRAF targeted therapy changes the treatment paradigm in melanoma","volume":"8","author":"Ribas","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"7653","key":"10.1016\/j.det.2022.07.017_bib88","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.det.2022.07.017_bib89","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/onc.2012.453","article-title":"NRAS mutant melanoma: biological behavior and future strategies for therapeutic management","volume":"32","author":"Fedorenko","year":"2013","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.det.2022.07.017_bib90","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jnci\/95.11.790","article-title":"Frequency of UV-Inducible NRAS Mutations in Melanomas of Patients With Germline CDKN2A Mutations","volume":"95","author":"Eskandarpour","year":"2003","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.det.2022.07.017_bib91","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","article-title":"Targeting T Cell Co-receptors for Cancer Therapy","volume":"44","author":"Callahan","year":"2016","journal-title":"Immunity"},{"issue":"5256","key":"10.1016\/j.det.2022.07.017_bib92","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.det.2022.07.017_bib93","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/35105024","article-title":"T-cell regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.det.2022.07.017_bib94","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib95","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.det.2022.07.017_bib96","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13578-018-0232-4","article-title":"Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1\/PD-L1 blockade mediated cancer immunotherapy?","volume":"8","author":"Tang","year":"2018","journal-title":"Cell Biosci"},{"issue":"26","key":"10.1016\/j.det.2022.07.017_bib97","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib98","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib99","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJMe2116892","article-title":"A\u00a0New Combination Immunotherapy in Advanced Melanoma","volume":"386","author":"Frampton","year":"2022","journal-title":"New Engl J Med"},{"issue":"13","key":"10.1016\/j.det.2022.07.017_bib100","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.3390\/ijms21134576","article-title":"Targeted Therapy in Melanoma and Mechanisms of Resistance","volume":"21","author":"Czarnecka","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.det.2022.07.017_bib101","first-page":"269","article-title":"LAG-3 in Cancer Immunotherapy","volume":"344","author":"Goldberg","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.det.2022.07.017_bib102","doi-asserted-by":"crossref","first-page":"101305","DOI":"10.1016\/j.smim.2019.101305","article-title":"Lymphocyte-Activation Gene 3 (LAG3): the Next Immune Checkpoint Receptor","volume":"42","author":"Ruffo","year":"2019","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.det.2022.07.017_bib104","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.det.2022.07.017_bib105","first-page":"2022","article-title":"NCCN Clinical Practice Guidelines in Oncology, Melanoma: Cutaneous","volume":"2","author":"Swetter","year":"2022","journal-title":"NCCN.org."},{"issue":"33","key":"10.1016\/j.det.2022.07.017_bib106","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic Therapy for Melanoma: ASCO Guideline","volume":"38","author":"Seth","year":"2020","journal-title":"JCO"},{"issue":"9","key":"10.1016\/j.det.2022.07.017_bib107","first-page":"18","article-title":"A\u00a0Global Review of Melanoma Follow-up Guidelines","volume":"6","author":"Trotter","year":"2013","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"1","key":"10.1016\/j.det.2022.07.017_bib108","first-page":"25","article-title":"Analysis of prognostic factors for melanoma patients","volume":"24","author":"Lideikait\u0117","year":"2017","journal-title":"Acta Med Litu"},{"issue":"9992","key":"10.1016\/j.det.2022.07.017_bib109","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.det.2022.07.017_bib110","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.det.2022.07.017_bib111","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.det.2022.07.017_bib112","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.det.2022.07.017_bib113","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion\u2013Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.det.2022.07.017_bib114","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.det.2022.07.017_bib115","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.det.2022.07.017_bib116","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1101\/gad.191999.112","article-title":"Melanoma: from mutations to medicine","volume":"26","author":"Tsao","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.det.2022.07.017_bib117","doi-asserted-by":"crossref","first-page":"615317","DOI":"10.3389\/fimmu.2020.615317","article-title":"LAG3\u2019s Enigmatic Mechanism of Action","volume":"11","author":"Graydon","year":"2020","journal-title":"Front Immunol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863522000699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863522000699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:47:12Z","timestamp":1760006832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863522000699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0733863522000699"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2022.07.017","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melanoma classification and management in the era of molecular medicine","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2022.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}